MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Zentalis Pharmaceuticals Inc

Closed

1.35 -1.46

Overview

Share price change

24h

Current

Min

1.32

Max

1.4

Key metrics

By Trading Economics

Income

-7.3M

-47M

Sales

27M

27M

EPS

-0.614

Profit margin

-176.706

Employees

166

EBITDA

5.3M

-46M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+294.34% upside

Dividends

By Dow Jones

Next Earnings

6 May 2025

Market Stats

By TradingEconomics

Market Cap

-11M

130M

Previous open

2.81

Previous close

1.35

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Sept 2024, 11:52 UTC

Major Market Movers

Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies

18 Jun 2024, 11:59 UTC

Major Market Movers

Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies

Peer Comparison

Price change

Zentalis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

294.34% upside

12 Months Forecast

Average 6.27 USD  294.34%

High 10 USD

Low 2.2 USD

Based on 11 Wall Street analysts offering 12 month price targets forZentalis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

5

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

N/A / 1.76Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.